As panic surrounding the coronavirus outbreak reaches new heights every day, a Texas-based pharmaceutical company is attempting to capitalize on the consternation with a cannabis extract.

Kali-Extracts Inc. is claiming its CBD formulation, RespRx, is a potential treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions including coronavirus symptoms.

The company didn’t immediately respond to The GrowthOp’s request for comment. However, on its website, Kali-Extracts states that the treatment has been years in the making, claiming that its CBD formulation is derived from a cannabis extraction process featured in the Journal of Cannabis Research. According to the research, cannabis oil extracts can help alleviate COPD symptoms through its anti-inflammatory properties.

“In conjunction with the research already conducted and the next phase of research now moving forward, the company has filed a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditions,” a statement from Kali-Extracts reads.

Not everyone is on board with the company’s claims, however. Dr. Paola Cubillos, medical director at Mississauga-based data company, CB2Insights, shared the claims on social media, saying, “Holy!!! This is going too far.” Meanwhile, Kevin McKernan, founder of Massachusetts-based life sciences company, Medicinal Genomics, tweeted, “Bummer. There is actually some exciting preliminary work on cannabinoids and viruses that are now getting sold before it’s (…) understood.”

The experiments, as noted in the study, are still in the early stages. The results to date are only enough to prompt further research into the effects of cannabis oil extract on pulmonary function.